upadacitinib · Rinvoq
Small molecule
Also known as ABT-494
Evidence outlook
Approved: Atopic Dermatitis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis (label: moderately to severely active UC or CD who have had an inadequate response, lost response or were...), Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Lupus Erythematosus · Phase 3Vitiligo · Phase 3 · filing submittedHidradenitis Suppurativa · Phase 3Alopecia Areata · Phase 3 · filing submitted
Also approved (11)
- Ankylosing Spondylitis RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Non-radiographic Axial Spondyloarthritis RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
- Polyarticular Juvenile Idiopathic Arthritis RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
- Giant Cell Arteritis RINVOQ is indicated for the treatment of adults with giant cell arteritis.
- Severe alopecia areata in adults and adolescents 12 years and older (Rinvoq)
- Marketing authorisation of Rinvoq (first indication RA); current EU label includes ulcerative colitis and Crohn's disease
- Non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy (Rinvoq)
- Moderately to severely active Crohn's disease with inadequate response to existing therapy
- Moderately to severely active ulcerative colitis with inadequate response to existing therapy
- Moderately to severely active ulcerative colitis and Crohn's disease
- Rheumatoid Arthritis RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. RINVOQ may be used as monotherapy or in combination with...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SELECT-NEXT NCT02675426 · Rheumatoid Arthritis This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001). Registry: NCT02675426 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 2017-04-21 | ACR20 at Week 12 (SELECT-NEXT): 64% (141/221) upadacitinib 15mg, 66% (145/219) upadacitinib 30mg, vs 36% (79/221) placebo; p<0.0001 for each dose vs placebo | Reliable signal | link ↗ |
View 5 more trials
SELECT-EARLY NCT02706873 · Rheumatoid Arthritis Participants were randomized and the study was quadruple-blinded (participant, care provider, investigator and outcomes assessor all masked), with methotrexate as an active comparator in over 1,000 patients. The primary comparisons -- ACR50 response at week 12 and DAS28(CRP)-based remission at week 24, both validated measures of rheumatoid arthritis disease activity -- were clearly met, with upadacitinib outperforming methotrexate by roughly 24 to 32 percentage points (p<0.001 for both doses). Registry: NCT02706873 | 3 | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis (Baseline and Week 12); Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global Analysis; Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global Analysis (Baseline and Week 12); Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global Analysis (Baseline to Week 24) 2018-03-15 | Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX | Reliable signal | link ↗ |
NCT03086343 NCT03086343 · Rheumatoid Arthritis (RA) Participants were randomized and the trial was quadruple-blinded, comparing oral upadacitinib 15 mg to intravenous abatacept, an active biologic comparator, in 612 evaluable rheumatoid arthritis patients. The primary comparison -- change in the validated DAS28(CRP) disease activity score at week 12 -- met its pre-specified non-inferiority margin, and the 95% confidence interval for the treatment difference fell entirely on the side favoring upadacitinib. Registry: NCT03086343 | 3 | Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12) 2019-06-13 | Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. | Reliable signal | link ↗ |
SELECT-MONOTHERAPY NCT02706951 · Rheumatoid Arthritis This was a randomized, double-blind trial of 648 patients that compared upadacitinib with an active comparator (continued methotrexate) using matching placebos. A power calculation planned 600 patients and 648 were enrolled, and both upadacitinib doses beat methotrexate on both primary endpoints, ACR20 response and DAS28-CRP low disease activity at week 14 (adjusted p<0.001). Registry: NCT02706951 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14 (Baseline and week 14); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14 2017-10-02 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
SELECT-COMPARE NCT02629159 · Rheumatoid Arthritis Participants were randomly assigned and fully blinded to upadacitinib, placebo or adalimumab, and upadacitinib beat placebo on both primary endpoints at week 12, ACR20 response and DAS28-CRP remission (both p<0.001). The protocol's sample-size calculation planned 1,500 participants, and 1,629 were enrolled. Registry: NCT02629159 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 2017-10-27 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
SELECT-BEYOND NCT02706847 · Rheumatoid Arthritis Participants were randomly assigned and fully blinded to upadacitinib 15 mg, 30 mg or placebo, and both doses beat placebo at week 12 on ACR20 response (64.6% and 56.4% vs 28.4%) and on DAS28-CRP low disease activity (both p<0.001). The protocol's sample-size calculation planned 450 participants, and 499 were enrolled. Registry: NCT02706847 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 2017-04-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (47)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Competitive landscape
Other JAK drugs
baricitinib, tofacitinib, filgotinib, ivarmacitinib, QLM3003 and 1 more. Compare all 7 JAK drugs
Other JAK1 drugs
abrocitinib, filgotinib, LW402, VC005, Zemprocitinib and 3 more. Compare all 9 JAK1 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Upadacitinib (Rinvoq): this drug | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001 | |
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | Reliable signal | NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9% | |
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | Reliable signal | NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18% | |
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | Partial signal | NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol). | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Weak signal | NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | |
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5) | |
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | Reliable signal | NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26% NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6% | |
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | Reliable signal | NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12% | |
| Ruxolitinib (Opzelura) | Approved | Small molecule | JAK1/2 | Reliable signal | NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14) | |
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | Reliable signal | NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9% NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18% | |
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) | |
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Asivatrep | Phase 3 | Small molecule | TRPV1 | Reliable signal | NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001) | |
| Baricitinib (Olumiant) | Phase 3 | Small molecule | JAK, JAK1/2 | Reliable signal | NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8% | |
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ivarmacitinib | Phase 3(overall) | Small molecule | JAK | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | No reviewed efficacy summary in this indication | |
| LW402 | Phase 3 | Small molecule | JAK1 | Partial signal | No reviewed efficacy summary in this indication | |
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| QLM3003 | Phase 3 | Small molecule | JAK | Partial signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). | |
| Rezpegaldesleukin | Phase 3 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1819 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Soficitinib (ICP-332) | Phase 3 | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| SSGJ-611 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Reliable signal | NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher) | |
| Telikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | Reliable signal | NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Bosakitug | Phase 2 | Monoclonal antibody | TSLP | Weak signal | NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9) | |
| Camoteskimab | Phase 2 | Monoclonal antibody | IL-18 | Partial signal | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| CMS-D001 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | Weak signal | Featured results are safety only in this race | |
| EVO101 | Phase 2 | Small molecule | IRAK4 | Partial signal | NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed | |
| EVO301 | Phase 2 | Protein / enzyme therapeutic | IL-18 | Partial signal | NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01) | |
| FB825 | Phase 2 | Monoclonal antibody | CεmX domain of membrane-bound IgE (mIgE) | Weak signal | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Galvokimig | Phase 2 | Multispecific antibody | IL-13, IL-17A, IL-17F | Partial signal | Featured results are safety only in this race | |
| GHZ339 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| GIA632 | Phase 2 | Monoclonal antibody | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 2 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| HY209gel | Phase 2 | Small molecule | GPCR19 / GPBAR1 (TGR5, bile acid receptor) | Partial signal | Featured results are safety only in this race | |
| IN-115314 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95597528 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| JYP0061 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | Weak signal | Featured results are safety only in this race | |
| Lepzacitinib | Phase 2 | Small molecule | JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| LNK01004 | Phase 2 | Small molecule | Pan-JAK | Partial signal | Featured results are safety only in this race | |
| LT-002-158 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Modzatinib | Phase 2 | Small molecule | ITK and JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mosedipimod | Phase 2 | Small molecule | NF-kB / CCL26 pathway | not yet graded | No reviewed efficacy summary in this indication | |
| Nitrosomonas Eutropha (B244) | Phase 2 | Microbiome therapeutic | live biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244) | Reliable signal | NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18) | |
| Olevaprubart | Phase 2 | Monoclonal antibody | OX40 | Weak signal | Featured results are safety only in this race | |
| Ompekimig | Phase 2 | Multispecific antibody | IL-4, IL-13, IL-33 | Partial signal | NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09). | |
| OpSCF | Phase 2 | Monoclonal antibody | Stem cell factor (SCF / KIT ligand) | Partial signal | NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073) | |
| Orismilast | Phase 2 | Small molecule | PDE4B/D | Partial signal | NCT05469464: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 (Baseline and Week 16): Orismilast Modified Release Tablets 20 mg BID -55.1% (Standard Error 4.89) | Orismilast Modified Release Tablets 30 mg BID -52.2% (Standard Error 5.39) | Orismilast Modified Release Tablets 40 mg BID -61.4% (Standard Error 5.02) vs Placebo Tablets BID -50.4% (Standard Error 4.98) missed NCT02496546: In adults with mild to moderate atopic dermatitis treated twice daily for 3 weeks, total sign score at end of treatment was 5.2 (least squares mean 5.1) with orismilast cream 20 mg/g versus 6.2 (LS mean 6.3) with vehicle, a statistically significant difference (P = .014). | |
| PF-08049820 | Phase 2 | Small molecule | STAT6 | not yet graded | No reviewed efficacy summary in this indication | |
| PUR 0110 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| QLS12010 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| ZL-82 | Phase 2 | Small molecule | JAK | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0449 | Phase 1(overall) | — | JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Londamocitinib | Discontinued | Small molecule | JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Tipasertideg | Discontinued | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 75 furthest-along competitors are listed; 40 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(47 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rinvoq (upadacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (6)
November 2026 (1)
What to watch
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
2027 (15)
January 2027 (1)
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
May 2027 (2)
June 2027 (2)
July 2027 (3)
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
November 2027 (2)
December 2027 (1)
What to watch
2028 (13)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
April 2028 (1)
What to watch
May 2028 (1)
What to watch
August 2028 (4)
What to watch
What to watch
What to watch
What to watch
September 2028 (2)
December 2028 (3)
What to watch
What to watch
What to watch
2029 (6)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
June 2029 (1)
What to watch
November 2029 (2)
December 2029 (1)
What to watch
2030 (3)
February 2030 (1)
What to watch
April 2030 (1)
What to watch
June 2030 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
2032 (2)
2035 (1)
June 2035 (1)
What to watch
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent